- Home
- MBOT vs CGTX Comparison
MBOT vs CGTX Comparison
Compare MBOT & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MBOT | CGTX |
|---|---|---|
| Founded | 2010 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.3M | 132.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MBOT | CGTX |
|---|---|---|
| Price | $2.15 | $1.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $8.75 | $3.33 |
| AVG Volume (30 Days) | ★ 1.6M | 897.3K |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3,119.61 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.25 | $0.22 |
| 52 Week High | $4.67 | $3.83 |
Technical Indicators
Market Signals| Indicator | MBOT | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.61 | 44.38 |
| Support Level | $1.95 | $1.33 |
| Resistance Level | $2.14 | $1.62 |
| Average True Range (ATR) | 0.11 | 0.11 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 51.39 | 25.00 |
Price Performance
Historical ComparisonAbout MBOT Microbot Medical Inc.
Microbot Medical Inc is a breakthrough medical device company. The group is focused on transforming endovascular procedures through advanced robotic technology. Microbot's LIBERTY Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and provider safety. With a robust intellectual property portfolio and a deep commitment to innovation, Microbot is shaping the future of endovascular care.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.